Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer's Disease : vimarsana.com

Results Show Positive Treatment Effect of CT1812 on Global and Regional Brain Activity Management Holding Webcast Conference Call at 8:00am ET Today NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-st...

Related Keywords

Netherlands , Amsterdam , Noord Holland , Daniel Kontoh Boateng , Aline Sherwood , Anthony Caggiano , Lisa Ricciardi , Jort Vijverberg , National Institute On Aging , Amsterdam University Medical Centers , Cognition Therapeutics Inc , Globenewswire Inc , Nasdaq , Amsterdam University Medical Center Alzheimer , Tiberend Strategic Advisors Inc , Management Holding Webcast Conference Call , Scienta Communications , Securities Exchange Commission , Results Show Positive Treatment Effect , Regional Brain , Holding Webcast Conference Call , Brain Awareness , During June , Private Securities Litigation Reform Act , Exchange Commission , Strategic Advisors ,